fda green list glp-1 import alert 66-80 The is proposing the removal of three drugs from the 503B bulks of active ingredients that outsourcing facilities can use to make compounded medicines, the agency announced on Thursday The FDA "Green List" -

00:13:29 Vickie Danaher And like we often see prior auths with the other GLP-1 agonists for obesity, we should expect prior auths for orforglipron too

Wondering why your friend pays $50 a month for a GLP-1 and you're quoted $500

Manipulative sales tactics CrazyLeaf employs a familiar playbook of psychological manipulation: Countdown timers creating false urgency ("Offer expires in 4:32!") Artificial scarcity warnings ("Only 3 boxes left!") Bulk discount structures ("Buy 3 get 2 free") designed to increase order value "Free shipping" timers ("Free global shipping if you order in the next 5 minutes") These are not the tactics of a company confident in its product

The BALANCE model offers one template for reform